Anna Protopapas

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Nathan McConarty, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Anna Protopapas

Form 4 holding Director

Mersana Therapeutics, Inc.

Security class
Restricted Stock Unit
Shares / value
0
Estimated value
$0
Report date
15 Jan 2025
Price
$0.5800
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Dicerna Pharmaceuticals Inc

Security class
Restricted Stock Units
Shares / value
0
Estimated value
Report date
03 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Nuvalent, Inc.

Security class
Class A Common Stock - Restricted Stock Units
Shares / value
0
Estimated value
Report date
15 Jul 2026
Price
Ownership
Direct

Insider Reports Filed by Anna Protopapas

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .